Floatz logo

TIPIRACIL

Desmoid

Parabilis Medicines, Inc.Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Desmoid cohort.

Asset / SponsorPhaseRating
Nivolumab
Parabilis Medicines, Inc.
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Nab-Rapamycin
Sarcoma Oncology Research Center, LLC
Phase 1/2CCC
Trifluridine
Parabilis Medicines, Inc.
Phase 1/2CCC
Fog-001
Parabilis Medicines, Inc.
Phase 1/2CCC

View all 9 →

Same molecule, other indications

TIPIRACIL is also rated in:

colorectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
69 / 100
View asset →
rectal cancerDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →